LYEL:NASDAQ
Lyell Immunopharma Inc
8,12 $
arrow_downward
-0,85%(-0,070) 1D
8,12 $
0,00% (0,00)
bedtimeAfter hours
Closed: 16 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
8,24 $
High
8,44 $
Low
7,92 $
Mkt. cap
198,98 млн
Avg. vol.
158,44 м.
Volume
194,96 м.
52-wk high
45,00 $
52-wk low
7,32 $
EPS
-12,01 $
Beta
-0,03
Shares outstanding
24,50 млн
No. of employees
161
Open
8,24 $
High
8,44 $
Low
7,92 $
Mkt. cap
198,98 млн
Avg. vol.
158,44 м.
Volume
194,96 м.
52-wk high
45,00 $
52-wk low
7,32 $
EPS
-12,01 $
Beta
-0,03
Shares outstanding
24,50 млн
No. of employees
161
News stories
From web sources and news partners
MyChesCo
·
6 минут бұрын
KQC Quantum Pursues $215 Million Valuation in Nasdaq SPAC Deal
Yahoo Finance
·
1 сағат бұрын
Michael Burry Warns of a Stock Market ‘Supervolcano’
TheStreet
·
36 минут бұрын
Jeffrey Gundlach sees a hidden danger beneath the S&P 500
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, Калифорния, Америка Құрама Штаттары
Sector-
Websitelyell.com